Third-generation c-met-targeting CAR-T, engineered with a fusion of CD28, 4-1BB and CD3ζ endodomains, was tested in an orthoptic RCC murine model, and suppressed tumour growth in 60% of mice, with histological demonstration of CAR+ and CD8+ T-cells in treated animals. The gene discussed is CD8A; the disease is neoplasm.